Internal Medicine, Infectious Disease · Houston, TX
NPI
1659334100
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
6431 Fannin St, 2.112 Msb
Houston, TX, 77030
Phone (713) 500-7140
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
258 services
Medicare patients, 2024
103
Average age 67
Drug cost, 2024
$3.1M
1,557 prescriptions
Company payments, 2025
$1,750
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rodrigo Hasbun was code 99233 (hospital e&m - subsequent), 107 times for 53 patients. In total Rodrigo Hasbun billed 258 services in 15 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-07-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 107 | 53 | $85.10 | $9,106 |
| 99214 Office E&M - Established | Office | 44 | 30 | $81.72 | $3,596 |
| 99223 Hospital E&M - Initial | Facility | 38 | 38 | $131.10 | $4,982 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 26 | 18 | $12.14 | $316 |
By year: 2022 $26K for 314 services; 2023 $45K for 442 services; 2024 $22K for 258 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rodrigo Hasbun prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 300 prescriptions and refills. In total Rodrigo Hasbun wrote 1,557 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 300 | 316 | 36 | $1.3M |
| Meropenem Generic | 78 | 78 | Under 11 | $17K |
| Ampicillin-Sulbactam Ampicillin Sod/Sulbactam Sod | 70 | 70 | Under 11 | $26K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 62 | 72 | Under 11 | $261K |
| Tivicay Dolutegravir Sodium | 43 | 43 | Under 11 | $114K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 41 | 51 | 18 | $683 |
| Fluconazole Generic | 37 | 49 | 12 | $1,427 |
| Minocycline Hcl Generic | 35 | 49 | 14 | $1,372 |
| Juluca Dolutegravir/Rilpivirine | 34 | 34 | Under 11 | $131K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 31 | 31 | Under 11 | $149K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 31 | 33 | Under 11 | $114K |
| Ivermectin Generic | 28 | 30 | Under 11 | $6,005 |
| Azithromycin Generic | 27 | 34 | Under 11 | $858 |
| Levofloxacin Generic | 27 | 27 | Under 11 | $558 |
| Amoxicillin Generic | 24 | 28 | Under 11 | $436 |
Brand drugs: 661 claims; generic drugs: 896 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rodrigo Hasbun $1,750 ($1,750 in general payments such as food, travel and fees) from 2 companies. The largest payer was Gilead Sciences, Inc. with $1,750.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 1 | $1,750 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.